

- **Name:** Tae Min Kim
 - **Current Position & Affiliation:** Clinical professor, Seoul National University Hospital
 - **Country:** Republic of Korea
-

• Educational Background:

- Mar 2008- Feb 2012: PhD, Molecular Oncology, Department of Medicine, Seoul National University, Seoul, Korea
- Mar 2003 - Feb 2005: M.Sc., Molecular Oncology, Department of Medicine, Graduate School, Seoul National University, Seoul, Korea
- Mar 1994 - Feb 2000: M.D., Seoul National University College of Medicine, Seoul, Korea

• Professional Experience:

- Since Sep 2018: Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital,
- Apr 2018 - Aug 2018 Adjunct Professor, Graduate School of Medical Science and Engineering, KAIST, Daejeon, Korea
- Sep 2013 - Aug 2018 Associate Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital
- Sep 2009 - Aug 2013 Assistant Professor, Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Hospital,

• Professional Organizations:

- Seoul National University Hospital, Seoul National University College of Medicine, Seoul National University Cancer Research Institute

• Main Scientific Publications (First or corresponding author):

1. Lee JK, Kim TM, Ju YS et al. Clonal History and Genetic Predictors of Transformation into Small Cell Carcinomas from Lung Adenocarcinomas. J Clin Oncol 2017; 35:3065-74
2. Gambacorti-Passerini C, Kim TM et al. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol 2018;93:607-14
3. Lee Y, Kim TM, et al. Pre-clinical Modeling of Osimertinib for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. J Thorac Oncol 2019;14:1556-66
4. Park S, Kim TM, et al. Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells. Cancer Lett 2020;495:135-44
5. Park HR, Kim TM, et al. Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFR T790M-mutant non-small cell lung cancer. J Thorac Oncol 2021;16:1859-71